ANTISENSE-OLIGONUKLEOTIDMODULATION DER RAF-GENEXPRESSION

Patent europeic · EP0863911 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP0863911
Numer da la dumonda
EP96916859
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
31-05-1996
Publitgà
16-09-1998
Concedì
24-04-2002
Stritgà
31-05-2015
Motiv
Taxa annuala betg pajada
Classas IPC
C07H 21/00 (2006.01)
A61K 31/70 (2006.01)
Prioritad
US 463912 05.06.1995
Dumonda PCT
PCT/US1996/008165 31.05.1996
Publicaziun PCT
WO1996/039415 12.12.1996
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 23-12-2015

    Stritgà, taxa betg pajada

    Published in Swissreg on 23.12.2015

  2. 30-05-2003

    Transferì

    Owner
    ISIS PHARMACEUTICALS, INC., 2292 Faraday Avenue, Carlsbad, CA 92008, USA, Novartis AG, Lichtstrasse 35, 4056 Basel → ISIS PHARMACEUTICALS, INC., 2292 Faraday Avenue, Carlsbad, CA 92008, USA

    Published in +pat+ No 10 in 2003

  3. 30-05-2003

    Represchentant inscrit

    Representative
    Patentanwälte, Schaad, Balass, Menzl & Partner AG, Dufourstrasse 101, 8034 Zürich

    Published in +pat+ No 10 in 2003

  4. 30-04-2002

    Concedì

    Published in PIDTJ No 8 in 2002

Partidas

Inventur

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.